EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

NCT05498389 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
115
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd.

Collaborators